SEC Form 4 · accession 0001437749-17-006971
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Edwardson
Officer — Chief Operations Officer
Period of report
Apr 21, 2017
Accepted (ET)
Apr 21, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Apr 21, 2017 | M | 42,913 | $0.09 | A | 91,184 | D | |
| Ordinary Shares | Apr 21, 2017 | M | 22,371 | $0.09 | A | 113,555 | D | |
| Ordinary Shares | Apr 21, 2017 | M | 21,460 | $0.26 | A | 135,015 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $0.09 | Apr 21, 2017 | M | 42,913 | D | — | Mar 31, 2020 | Ordinary Shares | 42,913 | 0 | D |
| Share Option (Right to Buy)F2 | $0.09 | Apr 21, 2017 | M | 22,371 | D | — | Sep 30, 2018 | Ordinary Shares | 22,371 | 0 | D |
| Share Option (Right to Buy)F3 | $0.26 | Apr 21, 2017 | M | 21,460 | D | — | Dec 31, 2021 | Ordinary Shares | 21,460 | 0 | D |
Explanation of responses
- F1Options became fully exercisable on March 31, 2014.
- F2Options became fully exercisable on September 30, 2012.
- F3Options became fully exercisable on December 31, 2015.